Ga-68 PSMA PET/CT在复发高级别胶质瘤中的应用:体内PSMA表达评估
融合PET/MR显示所有MRI检测到的49个病灶均有Ga-68 PSMA摄取增高,患者和病灶水平的MRI与PET一致性均为100%。复发胶质瘤病灶的SUVmax中位数6.0(IQR 4.4-8.2),SUVmean中位数3.3(IQR 2.8-3.7);MRI标记为放射性坏死的病灶未见示踪剂积聚。结论认为Ga-68 PSMA在评估HGG复发方面具有潜力,并因其诊疗一体化潜力而鼓励在此类患者中使用。
要点
- Ga-68 PSMA PET与MRI融合在检测复发高级别胶质瘤病灶时患者和病灶水平一致性均达100%。
- 复发胶质瘤病灶SUVmax中位数6.0(IQR 4.4-8.2),SUVmean中位数3.3(IQR 2.8-3.7)。
- MRI诊断为放射性坏死的病灶未见Ga-68 PSMA摄取,有助于鉴别复发与放射性坏死。
关键影像表现/征象
- MRI共检测到49个病灶,融合PET/MR显示所有病灶均有Ga-68 PSMA摄取增高。
- 多发病灶在融合PET/MR图像上显示更佳。
- MRI标记为放射性坏死的病灶未见示踪剂积聚。
诊断标准与关键数值
- 脑实质内示踪剂异常积聚超过对侧半球定义为阳性研究。
- 复发胶质瘤病灶SUVmax中位数6.0(IQR 4.4-8.2),SUVmean中位数3.3(IQR 2.8-3.7)。
- MRI与PET在患者和病灶水平检测的一致性均为100%。
临床应用与阅片要点
- Ga-68 PSMA PET/MR融合可辅助检测复发高级别胶质瘤病灶,多发病灶显示更佳。
- 对于MRI难以鉴别的复发与放射性坏死,Ga-68 PSMA PET可能提供额外信息(放射性坏死病灶未见摄取)。
局限性
- 单中心前瞻性研究,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: We planned this prospective study to evaluate PSMA expression in recurrent high-grade gliomas (rHGG), including anaplastic astrocytoma and glioblastoma using Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68 (HBED-CC)]- (Ga-68 PSMA) positron emission tomography (PET), with its theranostic potential in mind.
METHODS: This was a prospective study enrolling patients with clinical and MRI evidence of rHGG on follow-up. Three treated cases of HGG with RN on MRI were also included as negative controls. Abnormal tracer accumulation in the brain parenchyma, more than the contralateral hemisphere was interpreted as positive study. For semiquantitative analysis, a 3D spherical region of interest (ROI) was drawn around the site of the abnormal Ga-68 PSMA uptake, and the ratio of SUVmax of tumor (T) to SUVmax of the contralateral corresponding area (TBR) was calculated. Each patients' PSMA brain PET was fused to the corresponding MRI and reviewed for concordance.
RESULTS: Thirty patients were included in the study, a total of 49 lesions were detected on MRI, and fused PET/MR images showed increased Ga-68 PSMA uptake in all these lesions. Multifocal lesions were better appreciated on fused PET-MR images, and concordance between MRI and PET was 100 % for patient and lesion-wise detection. Recurrent glioma lesions showed SUVmax and SUVmean values (median and IQR) 6.0 (4.4-8.2) and 3.3 (2.8-3.7), respectively. Lesions labeled as radiation necrosis on MRI did not show tracer accumulation.
CONCLUSION: Ga-68 PSMA has potential utility for evaluating recurrence in HGG and its potential for theranostics would encourage its use in the evaluation of these patients.
引用
- Kumar A, ArunRaj ST, Bhullar K, et al. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo. Neuroradiology. 2021. PMID: 34648046. doi:10.1007/s00234-021-02828-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。